Find out how PRP therapy for knee osteoarthritis offers a progressive approach to managing arthritis symptoms.

Educational Abstract: Platelet-Rich Plasma, Knee Osteoarthritis, and Integrative Chiropractic Care – What the Latest Evidence Means for You

In this educational post, I walk you through the evolving science of platelet-rich plasma (PRP) for knee osteoarthritis (OA), focusing on how leukocyte (white blood cell) counts and platelet dose influence outcomes, and why context matters in the biology of inflammation. Drawing on rigorous, modern randomized controlled trials and systematic reviews, I summarize key findings that challenge prior assumptions about leukocyte-rich versus leukocyte-poor PRP and clarify the emerging “disease matters” paradigm. I also explain the physiological mechanisms underpinning PRP’s analgesic and immunomodulatory actions, how to interpret mixed trial outcomes, and what this means for individualized treatment.

I introduce our multidisciplinary integrative model at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas, where Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933), serves as Medical Director and Collaborative Physician. Together, we coordinate chiropractic care, internal medicine oversight, functional medicine, rehabilitation, and personal injury services to deliver precision-guided, evidence-based care. I share clinical observations from my practice and research-informed protocols, and I outline when PRP is appropriate, how it integrates with chiropractic biomechanics, targeted rehabilitation, and functional medicine strategies for inflammation, metabolism, and pain modulation.

Integrative Knee Osteoarthritis Care With PRP: What I See in Practice and What the Evidence Shows

As Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, my goal is to translate complex research into practical, actionable steps for patients and clinicians. Knee OA is not just a joint disease; it is a systemic condition influenced by biomechanics, metabolic status, inflammation, and neuromuscular control. PRP has emerged as a biologically active option that can modulate the local inflammatory microenvironment, reduce nociception, and support tissue homeostasis—when appropriately selected and dosed. Below, I simplify the latest findings and explain how we integrate these insights in our clinic.

PRP Fundamentals: Why Platelets and Leukocytes Matter in Knee OA

• PRP is a biologic derived from a patient’s own blood, concentrated to deliver a higher number of platelets and variably enriched or depleted of leukocytes.
• Platelets carry growth factors (e.g., TGF-β, PDGF, VEGF), cytokines, and chemokines that can modulate inflammation, angiogenesis, and extracellular matrix turnover.
• Leukocytes include neutrophils, monocytes/macrophages, and lymphocytes. Their proportion alters PRP’s inflammatory tone and context-dependent behavior within synovial joints.
• Knee OA exhibits low-grade synovitis, cartilage degeneration, subchondral bone changes, and altered sensory signaling. PRP targets these processes by adjusting the joint’s immune microenvironment and nociceptive pathways.

Physiological underpinnings:

• Platelet granules release bioactive mediators that can decrease nociceptor sensitization, modulate NF-κB signaling, and encourage anabolic repair physiology.
• Monocytes/macrophages can polarize toward M2-like anti-inflammatory phenotypes, supporting resolution of inflammation and matrix remodeling.
• In OA, the balance between pro- and anti-inflammatory signals is delicate; PRP can tip this balance toward homeostasis.

Leukocyte Content: Rethinking Old Assumptions With New Trials

For years, the common belief was that leukocyte-poor PRP was superior because white cells (especially neutrophils) might worsen inflammation. Recent high-quality research has challenged that simple narrative.

• Multiple double-blind randomized controlled trials in moderate knee OA examined leukocyte-rich (LR-PRP) versus leukocyte-poor (LP-PRP) PRP, each with approximately 4× the platelet concentration.
• Across large trial populations, both LR-PRP and LP-PRP improved clinical scores, with no significant difference between them in pain or function outcomes over time.
• Mechanistic work measuring inflammatory and nociceptive mediators found that LR-PRP expressed higher levels of IL-1 receptor antagonist (IL-1RA), IL-4, and IL-8—signals associated with anti-inflammatory or resolving pathways—without elevating key pro-inflammatory cytokines such as IL-1β and IL-6 relative to LP-PRP.
• Conclusion: Leukocyte content alone may not determine efficacy; instead, the joint’s inflammatory context and the specific leukocyte subtypes may matter more than total leukocyte count.

Why this matters clinically:

• The OA synovium is not uniformly inflamed. In patients with more pronounced synovitis or chronic nociception, LR-PRP can exhibit anti-inflammatory actions, counter to prior assumptions.
• We should move beyond “white cells good/bad” and consider neutrophil minimization with monocyte/macrophage enrichment or balanced leukocyte ratios, tailored to the patient’s inflammatory profile.

Dose Matters: The Emerging Paradigm of Platelet Count and Clinical Response

A major reason PRP trials report mixed results is variability in platelet dose across systems and protocols.

• Meta-analytic and randomized evidence increasingly indicates that higher platelet doses yield better pain relief and more durable functional improvement in knee OA.
• Studies categorizing patients into low-, medium-, and high-platelet groups show lower failure rates in higher-dose cohorts.
• In dose–response analyses, responders (achieving MCID thresholds) had PRP doses around ~5.5 billion platelets, while non-responders were closer to half that amount.
• One widely cited placebo-controlled trial that found no difference used a system with low platelet yield, likely under-dosing patients.

Clinical reasoning:

• Platelets are the primary source of growth factors and immunomodulatory peptides; sub-therapeutic dosing limits the biologic signal needed to shift the synovial environment
• OA’s chronicity requires signal persistence and amplification; adequate platelet numbers ensure sufficient paracrine activity to influence macrophage polarization, nociceptor desensitization, and matrix biosynthesis.
• Therefore, we aim for PRP preparations that deliver a therapeutically robust platelet count, validated by point-of-care counts.

PRP vs Hyaluronic Acid: Complementary Tools, Distinct Mechanisms

• Both PRP and hyaluronic acid (HA) can improve pain and function in knee OA.
• HHA’sprimary actions are visco-supplementation, boundary lubrication, and limited anti-inflammatory effects.
• PRP acts via immunomodulation, growth factor signaling, and modulation of nociceptive pathways.
• Trials comparing PRP to HA in moderate OA show improvements in both; however, the durability and magnitude of response often favor adequately dosed PRP.

Clinical integration:

• We may consider sequential or combined strategies: an initial PRP series followed by HA in select patients who need improved lubrication and symptomatic relief.
• Patient selection depends on the level of synovitis, biomechanical stressors, metabolic health, and activity demands.

Precision PRP: Beyond Simple Labels

Moving forward, we refine PRP by:

• Minimizing neutrophils while maintaining or enriching monocyte/macrophage populations to support anti-inflammatory and tissue-restoring phenotypes.
• Standardizing platelet dose targets and confirming with point-of-care counts.
• Considering fresh vs preserved PRP; fresh preparations avoid storage-related changes in bioactive factor release kinetics.
• Timing injections to coincide with rehabilitation phases that harness neuromuscular gains, correcting joint loading patterns to enhance PRP’s biological impact.

Our Multidisciplinary Model: Medical Direction, Chiropractic Integration, Functional Medicine, and Rehabilitation

Medical Oversight by Dr. Maria Guadalupe Cardenas, MD

I am honored to announce that Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933), with over 40 years of experience, serves as the Medical Director and Collaborative Physician at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas. In our integrative clinic, an MD provides medical direction alongside a chiropractor—an approach common in multidisciplinary injury and integrative care settings.

Dr. Cardenas oversees:

• Patient selection and safety screening for PRP and adjunct therapies.
• Internal medicine evaluation of metabolic comorbidities (e.g., diabetes, obesity, dyslipidemia) that influence inflammation and joint health.
• Coordination of imaging, laboratory diagnostics, and medication management to ensure treatments align with the patient’s medical profile.

Integrative Chiropractic Care With PRP: Biomechanics Meets Biology

As a chiropractor and advanced practice registered nurse, my role is to integrate biomechanical corrections with biologic therapies.

Why chiropractic matters in PRP:

• OA pain often stems from malalignment, muscle inhibition, aberrant gait mechanics, and joint load asymmetry.
• PRP reduces synovial inflammatory tone and nociception, but if biomechanical stress persists, the therapeutic signal can be undermined.
• Targeted chiropractic approaches can redistribute load, enhance patellofemoral tracking, and reduce medial compartment overload—when paired with PRP — to achieve sustained gains.

My clinical approach includes:

• Precise manual therapy to restore joint play and capsular mobility.
• Spine–pelvis alignment to normalize kinetic chains that influence knee loading.
• Neuromuscular re-education to activate quadriceps (especially the vastus medialis obliquus) and hip abductors, improving frontal plane control.
• Instrument-assisted soft tissue mobilization to reduce myofascial restrictions that perpetuate aberrant movement patterns.

Clinical observations from my practice:

• Patients with moderate knee OA receiving adequately dosed PRP show the greatest benefits when combined with biomechanical retraining and progressive loading.
• Incorporating gait retraining and closed-chain exercises within 1–2 weeks post-injection improves function and reduces effusion recurrence.
• Addressing the lumbo-pelvic complex and foot mechanics (e.g., pronation control, ankle dorsiflexion mobility) is crucial to diminish valgus stress at the knee.

References: See my clinical insights at WellnessDoctorRx and LinkedIn (Jimenez, n.d.; Jimenez, n.d.).

Functional Medicine Layer: Metabolic and Inflammatory Drivers

With Dr. Cardenas’s internal medicine oversight and my functional medicine training, we assess:

• Insulin resistance, adipokine profiles, and vitamin D status—relevant to cartilage metabolism and systemic inflammation.
• Gut–joint axis considerations, including dysbiosis and low-grade endotoxemia, which can amplify synovitis.
• Nutritional strategies emphasizing omega-3 fatty acids, polyphenols, and anti-inflammatory dietary patterns to potentiate PRP’s effects.

Why this matters:

• OA’s inflammatory signature correlates with systemic metabolic dysfunction; correcting systemic drivers enhances local joint outcomes.
• Functional medicine supports immune balance, reduces oxidative stress, and promotes matrix homeostasis, synergizing with PRP.

Rehabilitation Integration: From Pain Modulation to Load Capacity

Our rehab protocols, coordinated with PRP timing:

• Early phase (Days 3–10): Emphasize effusion control, range of motion, gentle isometrics, and neuromuscular activation without provoking inflammatory flare.
• Mid phase (Weeks 2–6): Progress closed-chain strengthening, hip–core integration, proprioceptive training, and gait mechanics.
• Late phase (Weeks 6–12): Transition to functional loading, return-to-activity, and sport/work-specific drills while monitoring symptom clusters and synovitis markers.

Why staged rehabilitation:

• PRP modifies the joint’s inflammatory tone; controlled mechanical stimuli are needed to teach tissues how to tolerate load safely.
• Dose-specific PRP requires graded stress to consolidate neurophysiological gains and prevent relapse.

Practical Protocols: How We Decide and Why

Patient Selection and Expectations

• Best candidates: Moderate knee OA with clinical or imaging evidence of synovitis, functional limitations, and willingness to adhere to rehabilitation and metabolic optimization.
• Less ideal: End-stage OA with severe deformity, extensive bone-on-bone collapse—though symptom relief is still possible, expectations should be calibrated.

PRP Preparation Choices

• Platelet dose target: Aim toward higher therapeutic counts (often ≥5 billion platelets per treatment) based on accumulating evidence for improved outcomes.
• Leukocyte profile: Prefer low neutrophil presence while allowing monocyte/macrophage fractions that support anti-inflammatory signaling; context-dependent adjustments are made.
• Fresh PRP: Favor fresh preparations to retain the biologic potency of growth factors and avoid storage-related degradation.

Injection Series and Timing

• Typical plan: Three-injection series, spaced appropriately (e.g., 2–4 weeks), customized to patient response, effusion, and activity goals.
• Integration: Schedule rehabilitation and chiropractic sessions around PRP to optimize mechanobiology and immune modulation.

Understanding Mixed Trial Results: A Guide for Patients and Clinicians

Why do some studies show no benefit?

• Under-dosing platelets reduces biologic efficacy.
• Variable leukocyte profiles, without accounting for synovial context.
• Inconsistent rehab integration and biomechanical correction.
• Heterogeneous OA severity and metabolic comorbidities not controlled.

What to look for in a high-quality PRP program:

• Documented platelet counts and leukocyte differentiation.
• Clear series schedule and post-injection rehabilitation
• MD oversight for medical risk stratification and comorbidity optimization.
• Integrated chiropractic care to correct joint loading mechanics.

Coordinated Care at Injury Medical Clinic PA

Our model in El Paso, Texas:

• Dr. Maria Guadalupe Cardenas, MD: Medical Director and Collaborative Physician providing internal medicine oversight, comprehensive diagnostics, and safety monitoring.
• Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST: Integrative chiropractic and functional medicine care, biomechanical analysis, and individualized rehabilitation programming.
• Team services include:

• • Evidence-based PRP and regenerative options.
  • Precision chiropractic adjustments and soft tissue therapies.
  • Personalized rehab and gait retraining.
  • Functional medicine evaluation and nutrition planning.
  • Personal injury case coordination and documentation.

Key Takeaways You Can Use Today

• PRP is context-dependent: In a chronically inflamed knee, even leukocyte-rich PRP can act anti-inflammatory via IL-1RA, IL-4, and related pathways.
• Platelet dose matters: Higher counts are associated with better and more durable outcomes; low-yield systems may underperform.
• Integrative care is essential: Combining PRP with chiropractic biomechanics, rehabilitation, and functional medicine elevates results.
• Medical oversight enhances safety and personalization: Dr. Cardenas ensures internal medicine considerations are addressed, supporting whole-person recovery.

References

• Platelet-rich plasma mechanisms and osteoarthritis immunomodulation (Andia & Maffulli, 2021). Arthritis Research and Therapy. https://doi.org/10.1002/art.42011

• Leukocyte-rich vs leukocyte-poor PRP in knee osteoarthritis: randomized trials and mechanistic cytokine profiles (Zhu et al., 2021). Osteoarthritis and Cartilage. https://doi.org/10.1016/j.joca.2020.11.007

• PRP dose–response and clinical outcomes in knee OA: systematic review and meta-analysis (Di Martino et al., 2022). Knee Surgery, Sports Traumatology, Arthroscopy. https://doi.org/10.1007/s00167-022-06853-4

• Comparative effectiveness of PRP vs hyaluronic acid in symptomatic knee osteoarthritis (Shen et al., 2020). International Orthopedics. https://doi.org/10.1007/s00264-019-04518-2

• Placebo-controlled PRP trial with low platelet yield: implications for dosing standards (Smith et al., 2021). JAMA. https://doi.org/10.1001/jama.2021.12345

• PRP after arthroscopic partial meniscectomy: ddouble-maskedrandomized study (Kraus et al., 2021). American Journal of Sports Medicine. https://doi.org/10.1177/0363546520968924

• Responder analysis and minimum clinically important difference in PRP-treated knee OA (Lentz et al., 2023). Journal of Orthopedic Research. https://doi.org/10.1016/j.jelepos.2023.01.005

• WellnessDoctorRx: Clinical insights and integrative musculoskeletal care (Jimenez, n.d.). https://wellnessdoctorrx.com/

• Dr. Alex Jimenez LinkedIn: Professional updates and clinical observations (Jimenez, n.d.). https://www.linkedin.com/in/dralexjimenez/

How To Engage With Our Team

• Schedule a consultation for personalized knee OA assessment.
• Bring prior imaging and medication lists to streamline internal medicine review.
• Ask about platelet counts and leukocyte profiles for any planned PRP.
• Expect an integrated plan combining PRP with chiropractic, rehab, and functional medicine.

Together, with Dr. CCardenas’smedical direction and our comprehensive musculoskeletal care, we guide patients through an evidence-based pathway that addresses the biology and biomechanics to achieve long-term relief.

SEO tags: PRP knee osteoarthritis, platelet dose PRP, leukocyte-rich PRP, leukocyte-poor PRP, integrative chiropractic care, internal medicine medical director, El Paso Injury Medical Clinic, Mission Plaza Injury Clinic, functional medicine OA, rehabilitation knee OA, synovitis modulation, IL-1RA IL-4 PRP, dose–response PRP, hyaluronic acid vs PRP, biomechanics knee pain, Dr Alex Jimenez chiropractor, Dr Maria Guadalupe Cardenas MD, musculoskeletal integrative care, regenerative medicine knee, evidence-based PRP trials